Actively Recruiting
Evaluating Safety and Dosage of Tarlatamab Combined with AB248 in Extensive Stage Small Cell Lung Cancer
Led by Amgen · Updated on 2026-09-25
380
Participants Needed
19
Research Sites
148 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and tolerability of the drug tarlatamab combined with AB248 in people who have extensive stage small cell lung cancer ES-SCLC that has progressed or returned after previous treatment. This Phase 1b study also aims to find the recommended dose of AB248 to use with tarlatamab, including exploring the maximum tolerated dose. The study is led by Amgen and focuses on treatment evaluation. Participants receive multiple dose levels of AB248 combined with tarlatamab, both given through intravenous infusions. The study has two parts a dose exploration phase to find the best dose of AB248 with tarlatamab, and a dose expansion phase to test the combination at the recommended dose. There may be an optional group testing lower doses or alternative dosing schedules of AB248 with tarlatamab. During the study, participants will be monitored for treatment-emergent adverse events and dose-limiting toxicities. Researchers will also measure drug levels in the blood and assess cancer response using RECIST 1.1 criteria over up to 2.5 years. Other outcomes include progression-free survival, overall survival, and antibody formation against AB248. The study involves repeated evaluations to understand safety, dosing, and effectiveness over time.
CONDITIONS
Brief Title
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here